ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0761

Development of a Symptom Diary for Use in Patients with Sjogren’s Syndrome

Briana Ndife1, Sheri Fenel2, Sandy Lewis2 and Neetu Agashivala3, 1Novartis, East Hanover, NJ, 2RTI Health Solutions, Research Triangle Park, NC, 3Novartis Pharmaceutical Corporation, East Hanover, NJ

Meeting: ACR Convergence 2021

Keywords: Patient reported outcomes, Sjögren's syndrome

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 7, 2021

Title: Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)

Session Type: Poster Session B

Session Time: 8:30AM-10:30AM

Background/Purpose: Sjögren’s Syndrome (SS) is a systemic autoimmune disease associated with a wide range of symptoms and long-term complications. While clinical indices are useful in diagnosis and assessment of disease activity, patient-reported outcome (PRO) measures are needed to measure the severity of symptoms from a patient perspective. The objective of this study was to develop a patient-reported diary for use in clinical trials to assess the severity of key symptoms of SS in alignment with Food and Drug Administration (FDA) PRO guidance documents.

Methods: Development began with targeted reviews of the literature and relevant PRO measures to identify symptoms of SS which are both highly prevalent in the patient population and have the potential to improve within the context and timeframe of a clinical trial. Following the development of an item pool addressing the initially identified symptoms, semi-structured interviews were conducted with clinical experts (n=2) to gather feedback on this preliminary item pool and to identify any additional concepts of importance. Following minor revisions to the draft items based on clinician feedback, three iterative sets of hybrid concept elicitation (CE) and cognitive debriefing (CD) interviews were conducted with a total of 17 patients with primary SS (64.7% female; median age 58.0 years [range 28-70 years]) to refine the diary and further assess its content validity.

Results: Based on the targeted literature review, the most prevalent symptoms of importance to patients with SS included dryness of the eyes, mouth, skin, and female genitalia along with fatigue and muscle or joint pain. While additional symptoms that tend to occur at later stages of the disease process were identified (e.g., brain fog, neuropathic pain), these symptoms would not be relevant across the full disease spectrum and thus were not included in the preliminary item pool. While the clinical experts generally endorsed the initial content of the diary, they recommended the exclusion of skin dryness, noting that this was not a common complaint among their patients.

The symptoms most commonly reported by patients participating in the qualitative interviews were consistent with those addressed in the preliminary item pool and final diary, including dry eyes (100%), dry mouth (100%), dry skin (47%), genital dryness (46% of female participants), fatigue (77%), and muscle or joint pain (53%). Of note, while the concept of skin dryness was not fully endorsed by the clinical experts, patients supported its inclusion in the final measure. With minor modifications, patients also indicated that the diary items were easy to understand and answer. Finally, no concept of importance was identified as missing from the diary by more than 3 of the 17 interview participants, and many of these were impacts rather than symptoms of SS (e.g., dental decay, depression).

Conclusion: The Sjögren’s Syndrome Symptom Diary is a content valid measure designed for use in clinical trials to assess the severity of the symptoms most commonly experienced by patients with SS. Following psychometric evaluation, this measure will have the potential to support product labeling claims.


Disclosures: B. Ndife, Novartis, 3, 11; S. Fenel, Novartis, 2; S. Lewis, Novartis, 2; N. Agashivala, Novartis, 3, 11.

To cite this abstract in AMA style:

Ndife B, Fenel S, Lewis S, Agashivala N. Development of a Symptom Diary for Use in Patients with Sjogren’s Syndrome [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/development-of-a-symptom-diary-for-use-in-patients-with-sjogrens-syndrome/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/development-of-a-symptom-diary-for-use-in-patients-with-sjogrens-syndrome/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology